Neuroimaging Reward, Behavioral Treatment, and Smoking Cessation

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

35

Participants

Timeline

Start Date

February 1, 2017

Primary Completion Date

May 28, 2021

Study Completion Date

May 27, 2022

Conditions
Smoking
Interventions
DRUG

Nicotine Patch

Both groups will receive nicotine patches (21 mg/d) to wear for 1 month prior to the quit date. After the quit date, both groups will wear the nicotine patch for 8 weeks (21 mg/d for 4 weeks, 14 mg/d for 2 weeks, and 7 mg/d for 2 weeks).

DRUG

SPECTRUM Nicotine Research Cigarettes (.03 mg)

For 1 month prior to their quit date, participants will switch to smoking SPECTRUM Nicotine Research Cigarettes instead of their usual brand.

BEHAVIORAL

Behavioral Activation

Participants in the BA+VLNC group will undergo 8 60-minute behavioral sessions (4 pre-quit, 1 on quit day, and 3 post-quit) including 15 min of standard smoking cessation counseling and 45 minutes of behavioral activation treatment. BA components will include activity monitoring, values assessment, activity scheduling, and social contracts.

BEHAVIORAL

Supportive Counseling

Participants in the VLNC Only group will undergo 8 60-minute behavioral sessions (4 pre-quit, 1 on quit day, and 3 post-quit) including 15 min of standard smoking cessation counseling and 45 minutes of supportive counseling and health education. Supportive counseling and health education will include empathic listening as well as informational content on topics of exercise, nutrition, sleep and relaxation.

Trial Locations (1)

27705

Duke University Medical Center, Durham

All Listed Sponsors
collaborator

National Institute on Drug Abuse (NIDA)

NIH

lead

Maggie M Sweitzer, PhD

OTHER

NCT02927847 - Neuroimaging Reward, Behavioral Treatment, and Smoking Cessation | Biotech Hunter | Biotech Hunter